查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
欧洲下一代乳癌诊断和筛检市场：分析和预测，2023-2032
市场调查报告书
商品编码
1413711

欧洲下一代乳癌诊断和筛检市场：分析和预测，2023-2032

Europe Next-Generation Breast Cancer Diagnostic and Screening Market: Analysis and Forecast, 2023-2032
出版日期: | 出版商: BIS Research | 英文 69 Pages | 商品交期: 1-5个工作天内

价格

欧洲下一代乳癌诊断和筛检市场预计将从 2023 年的 8.4 亿美元成长到 2032年终的25.7 亿美元，预测期内复合年增长率为 13.20%。

乳癌患者盛行率的增加、乳癌早期诊断意识的提高、对乳癌生物标记的有效筛检、预后预测、个体化治疗以及市场参与企业间联盟和合作增加的推动。

主要市场统计数据
预测期 2023-2032
2023年评估 8.4亿美元
2032年预测 25.7亿美元
复合年增长率 13.2%

由于先进医疗技术的早期采用、乳癌高发病率和强大的医疗基础设施等因素，欧洲下一代乳癌诊断和筛检市场正在经历显着增长。欧洲国家特别重视乳癌意识提升和筛检，促进将创新生物标记和基因检测纳入诊断。医疗机构、研究机构和行业相关人员之间的合作正在进一步提高诊断的准确性和效率，有助于改善患者的治疗结果。这些倡议反映了该地区应对乳癌挑战的承诺，预计将维持欧洲市场成长并加强乳癌管理。

本报告调查了欧洲下一代乳癌诊断和筛检市场，并提供了市场概况、市场成长的各种影响因素分析、市场规模趋势和预测、主要国家的详细分析、主要企业的分析等。我正在总结。

市场分类

细分 1：按国家/地区

  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙
  • 其他的

目录

执行摘要

调查范围

调查方法

第一章 肿瘤分子诊断市场

  • 概述
  • 癌症类型
  • 科技
  • 市场动态
  • 监管部门核准的产品

第二章 区域

  • 欧洲
    • 主要发现
    • 市场动态
    • 市场规模/预测

第三章市场：竞争基准化分析

  • 活跃的企业生态系统
  • 公司简介
    • Agendia Inc.
    • CENTOGENE NV
    • F. Hoffmann-La Roche Ltd.
Product Code: BHP1806SS

“The Europe Next-Generation Breast Cancer Diagnostic and Screening Market Expected to Reach $2.57 Billion by 2032.”

Introduction to Europe Next-Generation Breast Cancer Diagnostic and Screening Market

The Europe next-generation breast cancer diagnostic and screening market was valued at $0.84 billion in 2023 and is expected to reach $2.57 billion by the end of 2032, registering a CAGR of 13.20% during the forecast period 2023-2032. The growth in the next-generation breast cancer diagnostic and screening market is expected to be driven by the increase in the prevalence of breast cancer cases, rising awareness regarding early diagnosis of breast cancer, growing focus on breast cancer biomarkers for effective screening, prognosis, and personalized treatment, and increasing partnerships and collaborations amongst market players.

KEY MARKET STATISTICS
Forecast Period2023 - 2032
2023 Evaluation$0.84 Billion
2032 Forecast$2.57 Billion
CAGR13.2%

Market Introduction

The European Next-Generation Breast Cancer Diagnostic and Screening Market is experiencing significant growth driven by factors such as the region's early adoption of advanced medical technologies, a high prevalence of breast cancer, and a strong healthcare infrastructure. European countries prioritize breast cancer awareness and screening, fostering the integration of innovative biomarkers and genetic testing into diagnosis. Collaborations between healthcare institutions, research organizations, and industry players further enhance diagnostic accuracy and efficiency, contributing to improved patient outcomes. These efforts reflect the region's commitment to addressing breast cancer challenges and are expected to sustain market growth and enhance breast cancer management in Europe.

Market Segmentation:

Segmentation 1: by Country

  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest-of-Europe

How can this report add value to an organization?

Growth/Marketing Strategy: The Europe next-generation breast cancer diagnostic and screening market has seen major development by key players operating in the market, such as business expansions, partnerships, collaborations, mergers and acquisitions, product launches, and funding activities. Partnerships, alliances, and business expansions accounted for the maximum number of key developments in the Europe next-generation breast cancer diagnostic and screening market, followed by regulatory and legal activities and mergers and acquisitions.

Competitive Strategy: Key players in the Europe next-generation breast cancer diagnostic and screening market analyzed and profiled in the study involve players that offer next-generation breast cancer diagnostic and screening products and services. Moreover, comprehensive competitive strategies such as partnerships, agreements, collaborations, product launches and approvals, and funding scenarios will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and regional presence.

Some of the prominent names in this market are:

  • Agendia Inc.
  • CENTOGENE N.V.
  • F. Hoffmann-La Roche Ltd.

Table of Contents

Executive Summary

Scope of the Study

Research Methodology

1. Oncology Molecular Diagnostic Market

  • 1.1. Overview
  • 1.2. Cancer Type
  • 1.3. Technology
  • 1.4. Market Dynamics
  • 1.5. Regulatory-Approved Products

2. Regions

  • 2.1. Europe
    • 2.1.1. Key Findings
    • 2.1.2. Market Dynamics
      • 2.1.2.1. Impact Analysis
    • 2.1.3. Market Sizing and Forecast
      • 2.1.3.1. Europe Next-Generation Breast Cancer Diagnostic and Screening Market (by Country)
        • 2.1.3.1.1. Germany
          • 2.1.3.1.1.1. Market Dynamics
          • 2.1.3.1.1.2. Market Sizing and Forecast
        • 2.1.3.1.2. France
          • 2.1.3.1.2.1. Market Dynamics
          • 2.1.3.1.2.2. Market Sizing and Forecast
        • 2.1.3.1.3. U.K.
          • 2.1.3.1.3.1. Market Dynamics
          • 2.1.3.1.3.2. Market Sizing and Forecast
        • 2.1.3.1.4. Italy
          • 2.1.3.1.4.1. Market Dynamics
          • 2.1.3.1.4.2. Market Sizing and Forecast
        • 2.1.3.1.5. Spain
          • 2.1.3.1.5.1. Market Dynamics
          • 2.1.3.1.5.2. Market Sizing and Forecast
        • 2.1.3.1.6. Rest-of-Europe
          • 2.1.3.1.6.1. Market Dynamics
          • 2.1.3.1.6.2. Market Sizing and Forecast

3. Markets - Competitive Benchmarking

  • 3.1. Next-Generation Breast Cancer Diagnostic and Screening Active Players Ecosystem
  • 3.2. Company Profiles
    • 3.2.1. Agendia Inc.
      • 3.2.1.1. Company Overview
      • 3.2.1.2. Role of Agendia Inc. in the Next-Generation Breast Cancer Diagnostic and Screening Market
      • 3.2.1.3. Recent Developments
      • 3.2.1.4. Analyst Perception
    • 3.2.2. CENTOGENE N.V.
      • 3.2.2.1. Company Overview
      • 3.2.2.2. Role of CENTOGENE N.V. in the Next-Generation Breast Cancer Diagnostic and Screening Market
      • 3.2.2.3. Financials
      • 3.2.2.4. Recent Developments
      • 3.2.2.5. Analyst Perception
    • 3.2.3. F. Hoffmann-La Roche Ltd.
      • 3.2.3.1. Company Overview
      • 3.2.3.2. Role of F. Hoffmann-La Roche Ltd. in the Next-Generation Breast Cancer Diagnostic and Screening Market
      • 3.2.3.3. Financials
      • 3.2.3.4. Recent Developments
      • 3.2.3.5. Analyst Perception

List of Figures

  • Figure 1: Worldwide Breast Cancer Statistics (by Region), 2020
  • Figure 2: Europe Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
  • Figure 3: Next-Generation Breast Cancer Diagnostic and Screening Market (by Region), $Million, 2022 and 2032
  • Figure 4: Next-Generation Breast Cancer Diagnostic and Screening Market, Impact Analysis
  • Figure 5: Next-Generation Breast Cancer Diagnostic and Screening Market, Key Development Analysis, January 2019-April 2023
  • Figure 6: Next-Generation Breast Cancer Diagnostic and Screening Market: Research Methodology
  • Figure 7: Primary Research Methodology
  • Figure 8: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 9: Top-Down Approach (Segment-Wise Analysis)
  • Figure 10: Oncology Molecular Diagnostic Market, Solid Tumor, $Million, 2022 and 2032
  • Figure 11: Oncology Molecular Diagnostic Market, Hematological Malignancy, $Million, 2022 and 2032
  • Figure 12: Oncology Molecular Diagnostic Market, Market Dynamics
  • Figure 13: Next-Generation Breast Cancer Diagnostic and Screening Market Share (by Region), 2022-2032
  • Figure 14: Europe Next-Generation Breast Cancer Diagnostic and Screening Market, Incremental Opportunity (by Country), $Million, 2023-2032
  • Figure 15: Europe Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
  • Figure 16: Europe Next-Generation Breast Cancer Diagnostic and Screening Market (by Country), Share (%), 2022 and 2032
  • Figure 17: Germany Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
  • Figure 18: France Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
  • Figure 19: U.K. Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
  • Figure 20: Italy Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
  • Figure 21: Spain Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
  • Figure 22: Rest-of-Europe Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
  • Figure 23: Agendia Inc.: Product Portfolio
  • Figure 24: CENTOGENE N.V.: Product Portfolio
  • Figure 25: CENTOGENE N.V.: Overall Financials, $Million, 2019-2021
  • Figure 26: CENTOGENE N.V.: Net Revenue (by Segment), $Million, 2019-2021
  • Figure 27: CENTOGENE N.V.: Net Revenue (by Region), $Million, 2019-2021
  • Figure 28: CENTOGENE N.V.: R&D Expenditure, $Million, 2019-2021
  • Figure 29: F. Hoffmann-La Roche Ltd.: Product Portfolio
  • Figure 30: F. Hoffmann-La Roche Ltd.: Overall Financials, $Million, 2020-2022
  • Figure 31: F. Hoffmann-La Roche Ltd.: Net Revenue (by Segment), $Million, 2020-2022
  • Figure 32: F. Hoffmann-La Roche Ltd.: R&D Expenditure, $Million, 2020-2022

List of Tables

  • Table 1: Key Questions Answered in the Report
  • Table 2: Some of the Regulatory-Approved Oncology Molecular Diagnostic Products/Services for Different Types of Solid Tumors
  • Table 3: Europe Next-Generation Breast Cancer Diagnostic and Screening Market, Impact Analysis
  • Table 4: Next-Generation Breast Cancer Diagnostic and Screening Active Players Ecosystem
  • Table 5: Agendia Inc.: Key Services and Features
  • Table 6: CENTOGENE N.V.: Key Services and Features
  • Table 7: F. Hoffmann-La Roche Ltd.: Key Products and Features